Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P100046/S020

Synergy Ablation System

AtriCure, Inc. · Decision date May 6, 2026

FDA DECISIONP100046/S020

What did the FDA approve?

FDA records P100046/S020 as a supplement to PMA P100046, with the supplement type “Special (Immediate Track)”. The recorded decision is approval, dated May 6, 2026.

FDA approval order statement

approval for labeling changes intended to enhance the safe use of the device
Regulatory pathway
PMA supplement
Supplement type
Special (Immediate Track)
Clinical specialty
Cardiovascular
Decision date
May 6, 2026
FDA change category
Labeling Change - Indications/instructions/shelf life/tradename

FDA source record

Regulatory record facts

Identifier
P100046/S020
Regulatory pathway
PMA supplement
Product code
OCM
Decision code
APPR
Decision date
May 6, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Surgical cardiac ablation device, for treatment of atrial fibrillation.

Product code
OCM
FDA device class
3

For the original device and its historical approval scope, see PMA P100046. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P100046 · Original PMA

    ATRICURE SYNERGY ABLATION SYSTEM

  2. P100046/S020 received

    Application receipt date recorded by FDA.

  3. P100046/S020 · FDA decision

    Special (Immediate Track)

  4. P100046/S021 · Related supplement

    Synergy Ablation System

Timeline entries are records held by MedtechLedger for P100046. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P100046

Product / regulatory recordCompanyPathwayDecision dateSource
AtriCure, Inc.PMA approvalDec 14, 2011FDA
AtriCure, Inc.PMA supplementSep 24, 2026FDA

Explore the linked device profile

Other records with product code OCM

Product / regulatory recordCompanyPathwayDecision dateSource
AtriCure, Inc.PMA supplementSep 24, 2026FDA
AtriCure, Inc.PMA supplementMay 6, 2026FDA
AtriCure, Inc.PMA supplementNov 14, 2025FDA
AtriCure, Inc.PMA supplementOct 7, 2025FDA
AtriCure, Inc.PMA approvalApr 28, 2021FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

AtriCure, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
7555 Innovation Way, Mason, OH, 45040

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records